Pd 1pd L1 Blockade | List of Frontiers open access articles

Review

Published on 02 Jul 2019

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

in Drugs Outcomes Research and Policies

Jiqiao Yang
Xiujing He
Qing Lv
Jing Jing
Hubing Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2019.00726

10,247 views
29 citations

Review

Published on 21 Nov 2018

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC

in Cancer Immunity and Immunotherapy

Weimin Lin
Miao Chen
Le Hong
Hang Zhao
Qianming Chen

Frontiers in Oncology

doi 10.3389/fonc.2018.00532

12,062 views
40 citations

Mini Review

Published on 12 Mar 2020

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

in Cancer Immunity and Immunotherapy

Youhai Jiang
Xiaofang Zhao
Jing Fu
Hongyang Wang

Frontiers in Immunology

doi 10.3389/fimmu.2020.00339

31,506 views
109 citations

Review

Published on 28 May 2020

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review

in Cancer Immunity and Immunotherapy

Bin Li
Cong Yan
Jiamin Zhu
Xiaobing Chen
Qihan Fu
Hangyu Zhang
Zhou Tong
Lulu Liu
Yi Zheng
Peng Zhao

Frontiers in Immunology

doi 10.3389/fimmu.2020.01037

23,645 views
100 citations

Original Research

Published on 15 Aug 2022

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

in Cancer Immunity and Immunotherapy

Zhang-Wei Hu
Wei Sun
Yi-Hui Wen
Ren-Qiang Ma
Lin Chen
Wen-Qing Chen
Wen-Bin Lei
Wei-Ping Wen

Frontiers in Immunology

doi 10.3389/fimmu.2022.952059

7,546 views
29 citations

Original Research

Published on 25 Aug 2023

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer

in Cancer Immunity and Immunotherapy

Yangyang Ma
Yanli Xing
Hongmei Li
Ting Yuan
Bing Liang
Rongrong Li
Jianyu Li
Zhonghai Li
Shuying Li
Lizhi Niu

Frontiers in Immunology

doi 10.3389/fimmu.2023.1193040

4,734 views
19 citations

Review

Published on 25 May 2021

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

in Thoracic Oncology

Kenneth K. W. To
Winnie Fong
William C. S. Cho

Frontiers in Oncology

doi 10.3389/fonc.2021.635007

50,317 views
144 citations

Review

Published on 27 Jun 2022

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer

in Cancer Immunity and Immunotherapy

Yuedi Zhang
Qiulin Cui
Manman Xu
Duo Liu
Shuzhong Yao
Ming Chen

Frontiers in Immunology

doi 10.3389/fimmu.2022.901772

12,086 views
36 citations

Review

Published on 24 Nov 2022

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies

in Cancer Immunity and Immunotherapy

Meng Chen
Chenyan Li
Mingjun Sun
Yiling Li
Xuren Sun

Frontiers in Immunology

doi 10.3389/fimmu.2022.1043517

5,699 views
6 citations

Mini Review

Published on 22 Sep 2021

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade

in Cancer Molecular Targets and Therapeutics

Tian Tian
Zhaoming Li

Frontiers in Oncology

doi 10.3389/fonc.2021.731175

17,874 views
85 citations

Review

Published on 15 Feb 2023

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

in Pharmacology of Anti-Cancer Drugs

Man Wang
Lijie Zhu
Xiaoxu Yang
Jiahui Li
Yu’e Liu
Ying Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1132158

8,895 views
17 citations

Review

Published on 24 Aug 2023

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy

in Cancer Immunity and Immunotherapy

Ali Razaghi
Mickaël Durand-Dubief
Nele Brusselaers
Mikael Björnstedt

Frontiers in Immunology

doi 10.3389/fimmu.2023.1249330

11,435 views
29 citations

Original Research

Published on 11 Feb 2020

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion

in Cancer Immunity and Immunotherapy

Maite Alvarez
Federico Simonetta
Jeanette Baker
Alyssa R. Morrison
Arielle S. Wenokur
Antonio Pierini
Pedro Berraondo
Robert S. Negrin

Frontiers in Immunology

doi 10.3389/fimmu.2020.00007

10,321 views
38 citations

Review

Published on 22 Jul 2022

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes

in Pharmacology of Anti-Cancer Drugs

Dan Zheng
Xiaolin Hou
Jing Yu
Xiujing He

Frontiers in Pharmacology

doi 10.3389/fphar.2022.928369

7,389 views
10 citations

Review

Published on 24 Mar 2023

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

in Pharmacology of Anti-Cancer Drugs

Xin Zhang
Xuemei Wang
Lijian Hou
Zheng Xu
Yu’e Liu
Xueju Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1130937

7,728 views
28 citations

Review

Published on 07 Apr 2022

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism

in Cancer Immunity and Immunotherapy

Jianqiong Yin
Yuanjun Wu
Xue Yang
Lu Gan
Jianxin Xue

Frontiers in Immunology

doi 10.3389/fimmu.2022.830631

30,421 views
92 citations

Articles

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism